Quantcast

Latest Sunitinib Stories

965200e406012e5cd3869744713bf56e1
2009-03-13 07:15:00

Pfizer Inc. announced on Thursday that it had halted a successful trial of its cancer drug Sutent after results showed the drug slowed the progression of a rare form of pancreatic cancer.Compared to standard treatment and a placebo, Sutent substantially improved progression-free survival, the trial showed.  The company halted the trial after an independent safety board monitoring the late-stage study issued a positive recommendation.Because the trial was stopped early, patients will have...

2009-02-26 07:00:00

Pfizer's Axitinib Earns Decision Resources' Gold-Standard for Renal Cell Carcinoma in 2012, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a first-line therapy for metastatic renal cell carcinoma that can increase overall survival in comparison with Pfizer's Sutent would earn a 50 percent patient share in the United States...

2008-12-12 23:30:46

A British oncologist says he is dismayed that kidney cancer patients may be denied four new treatments due to cost. Dr. Tim Eisen of the University of Cambridge reports in BJU International that the National Institute for Health and Clinical Excellence has provisionally decided sunitinib, sorafenib, temsirolimus and interferon plus bevacizumab are too costly. While none of these new drugs cure the condition, they sometimes can extend life, Eisen said. For instance, some patients taking...

2008-11-11 09:00:47

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, has met the primary endpoint for the efficacy portion of the open label Phase I/II study of MKC-1 in combination with pemetrexed in non-small cell lung cancer patients. The Phase I/II study was designed to first evaluate a dose of MKC-1 to be used safely in combination with pemetrexed (Alimta) to treat patients with advanced non-small cell lung cancer (NSCLC)....

2008-10-27 12:00:30

Infinity Pharmaceuticals, a cancer drug discovery and development company, has initiated a Phase III registration trial of IPI-504, its lead inhibitor of heat shock protein 90, in patients with refractory gastrointestinal stromal tumors. The Ring trial is a randomized, double-blind, placebo-controlled study evaluating approximately 200 patients with refractory gastrointestinal stromal tumors (GIST) in over 20 countries and 50 sites worldwide. Patients whose tumors have grown despite...

2008-10-23 09:00:38

ZymoGenetics, a developer of novel protein therapeutics, has announced positive interim results from a Phase II clinical trial evaluating interleukin 21 in combination with Nexavar tablets in patients with metastatic renal cell cancer. Outpatient therapy with interleukin 21 (IL-21) and Nexavar as a second or third-line therapy for metastatic renal cell cancer was associated with anti-tumor activity, with manageable side effects. Of subjects treated and assessed by independent review, three...

2008-10-22 15:00:13

CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced new data from early non-clinical studies of Millennium/Takeda-discovered pipeline molecules highlighting novel therapeutic pathways in oncology. MLN4924 data build on the growing body of evidence supporting the importance of the Millennium-discovered Nedd8 Activating Enzyme (NAE) in tumor growth and survival. It is a first-in-class small molecule inhibitor of NAE. Both clinical and non-clinical...

2008-10-22 06:00:08

ZymoGenetics, Inc. (NASDAQ: ZGEN) presented interim results today from a Phase 2 clinical trial evaluating Interleukin 21 (IL-21) in combination with Nexavar(R) (sorafenib) tablets in patients with metastatic renal cell cancer. Outpatient therapy with IL-21 and Nexavar as a second or third-line therapy for metastatic renal cell cancer was associated with anti-tumor activity, with manageable side effects. Of subjects treated and assessed by independent review, 3 of 18 patients had a confirmed...

2008-10-16 09:00:42

Exelixis, Inc. (Nasdaq:EXEL) announced today that it will present 15 posters on the company's investigational compounds at the 20th Annual European Organization for Research and Treatment of Cancer-National Cancer Institute-American Academy of Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer Therapeutics," which will be held October 21-October 24 in Geneva, Switzerland. The titles, schedules, and locations for the poster presentations are provided below. Note that...

2008-10-14 09:00:45

WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, of the many targeted cancer agents in Phase III clinical trials in the adjuvant setting, surveyed oncologists say that Genentech/Roche/Chugai's Avastin in early-stage colorectal cancer holds the most promise to achieve regulatory approval. Additionally, more than half of surveyed oncologists indicated that the minimum benefit...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.